Top

Published in:

01-12-2019 | Glioblastoma | Review

Radioimmunotherapy (RIT) in Brain Tumors

Authors: Ali Gholamrezanezhad, Hossein Shooli, Narges Jokar, Reza Nemati, Majid Assadi

Published in: Nuclear Medicine and Molecular Imaging | Issue 6/2019

Abstract

Annually, the incidence of brain tumors has slightly increased and also the patient prognosis is still disappointing, especially for high-grade neoplasms. So, researchers seek methods to improve therapeutic index as a critical aim of treatment. One of these new challenging methods is radioimmunotherapy (RIT) that involves recruiting a coupling of radionuclide component with monoclonal antibody (mAb) which are targeted against cell surface tumor–related antigens or antigens of cells within the tumor microenvironment. In the context of cancer care, precision medicine is exemplified by RIT; precision medicine can offer a tailored treatment to meet the needs for treatment of brain tumors. This review aims to discuss the molecular targets used in radioimmunotherapy of brain tumors, available and future radioimmunopharmaceutics, clinical trials of radioimmunotherapy in brain neoplasms, and eventually, conclusion and future perspective of application of radioimmunotherapy in neurooncology cancer care.

Chhabda S, Carney O, D’Arco F, Jacques TS, Mankad K. The 2016 World Health Organization classification of tumours of the central nervous system: what the paediatric neuroradiologist needs to know. Quant Imaging Med Surg. 2016;6:486.PubMedPubMedCentral

Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009;10:459–66.PubMed

Stummer W, Pichlmeier U, Meinel T, Wiestler OD, Zanella F, Reulen H-J, et al. Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. Lancet Oncol. 2006;7:392–401.PubMed

Gaspar LE, Fisher BJ, Macdonald DR, Leber DV, Halperin EC, Schold SC, et al. Supratentorial malignant glioma: patterns of recurrence and implications for external beam local treatment. Int J Radiat Oncol Biol Phys. 1992;24:55–7.PubMed

Pouget J-P, Navarro-Teulon I, Bardiès M, Chouin N, Cartron G, Pèlegrin A, et al. Clinical radioimmunotherapy—the role of radiobiology. Nat Rev Clin Oncol. 2011;8:720.PubMed

Herold-Mende C, Mueller MM, Bonsanto MM, Schmitt HP, Kunze S, Steiner HH. Clinical impact and functional aspects of tenascin-C expression during glioma progression. Int J Cancer. 2002;98:362–9.PubMed

Martin D, Brown-Luedi M, Chiquet-Ehrismann R. Tenascin-C signaling through induction of 14-3-3 tau. J Cell Biol. 2003;160:171–5.PubMedPubMedCentral

Leins A, Riva P, Lindstedt R, Davidoff MS, Mehraein P, Weis S. Expression of tenascin-C in various human brain tumors and its relevance for survival in patients with astrocytoma. Cancer. 2003;98:2430–9.PubMed

Kim CH, Bak KH, Kim YS, Kim JM, Ko Y, Oh SJ, et al. Expression of tenascin-C in astrocytic tumors: its relevance to proliferation and angiogenesis. Surg Neurol. 2000;54:235–40.PubMed

10.

Ventimiglia JB, Wikstrand CJ, Ostrowski LE, Bourdon MA, Lightner VA, Bigner DD. Tenascin expression in human glioma cell lines and normal tissues. J Neuroimmunol. 1992;36:41–55.PubMed

11.

Brack SS, Silacci M, Birchler M, Neri D. Tumor-targeting properties of novel antibodies specific to the large isoform of tenascin-C. Clin Cancer Res. 2006;12:3200–8.PubMed

12.

De Santis R, Albertoni C, Petronzelli F, Campo S, D'Alessio V, Rosi A, et al. Low and high tenascin-expressing tumors are efficiently targeted by ST2146 monoclonal antibody. Clin Cancer Res. 2006;12:2191–6.PubMed

13.

Petronzelli F, Pelliccia A, Anastasi AM, D’Alessio V, Albertoni C, Rosi A, et al. Improved tumor targeting by combined use of two antitenascin antibodies. Clin Cancer Res. 2005;11:7137s–45s.PubMed

14.

Paganelli G, Bartolomei M, Grana C, Ferrari M, Rocca P, Chinol M. Radioimmunotherapy of brain tumor. Neurol Res. 2006;28:518–22.PubMed

15.

Reardon DA, Akabani G, Edward Coleman R, Friedman AH, Friedman HS, Herndon JE, et al. Phase II trial of murine 131I-labeled antitenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomas. J Clin Oncol. 2002;20:1389–97.PubMed

16.

Riva P, Franceschi G, Frattarelli M, Lazzari S, Riva N, Giuliani G, et al. Loco-regional radioimmunotherapy of high-grade malignant gliomas using specific monoclonal antibodies labeled with 90Y: a phase I study. Clin Cancer Res. 1999;5:3275s–80s.PubMed

17.

Reardon DA, Zalutsky MR, Bigner DD. Antitenascin-C monoclonal antibody radioimmunotherapy for malignant glioma patients. Expert Rev Anticancer Ther. 2007;7:675–87.PubMed

18.

Riva P, Franceschi G, Riva N, Casi M, Santimaria M, Adamo M. Role of nuclear medicine in the treatment of malignant gliomas: the locoregional radioimmunotherapy approach. Eur J Nucl Med. 2000;27:601–9.PubMed

19.

Riva P, Franceschi G, Frattarelli M, Riva N, Guiducci G, Cremonini AM, et al. 131I radioconjugated antibodies for the locoregional radioimmunotherapy of high-grade malignant glioma: phase I and II study. Acta Oncol. 1999;38:351–9.PubMed

20.

Herbst RS. Review of epidermal growth factor receptor biology. Int J Radiat Oncol Biol Phys. 2004;59:S21–S6.

21.

Brennan CW, Verhaak RG, McKenna A, Campos B, Noushmehr H, Salama SR, et al. The somatic genomic landscape of glioblastoma. Cell. 2013;155:462–77.PubMedPubMedCentral

22.

Westphal M, Heese O, Steinbach JP, Schnell O, Schackert G, Mehdorn M, et al. A randomised, open label phase III trial with nimotuzumab, an anti-epidermal growth factor receptor monoclonal antibody in the treatment of newly diagnosed adult glioblastoma. Eur J Cancer. 2015;51:522–32.PubMed

23.

Brown PD, Krishnan S, Sarkaria JN, Wu W, Jaeckle KA, Uhm JH, et al. Phase I/II trial of erlotinib and temozolomide with radiation therapy in the treatment of newly diagnosed glioblastoma multiforme: North Central Cancer Treatment Group Study N0177. J Clin Oncol. 2008;26:5603.PubMedPubMedCentral

24.

Prados MD, Chang SM, Butowski N, DeBoer R, Parvataneni R, Carliner H, et al. Phase II study of erlotinib plus temozolomide during and after radiation therapy in patients with newly diagnosed glioblastoma multiforme or gliosarcoma. J Clin Oncol. 2009;27:579.PubMed

25.

Chakravarti A, Wang M, Robins HI, Lautenschlaeger T, Curran WJ, Brachman DG, et al. RTOG 0211: a phase 1/2 study of radiation therapy with concurrent gefitinib for newly diagnosed glioblastoma patients. Int J Radiat Oncol Biol Phys. 2013;85:1206–11.PubMed

26.

Uhm JH, Ballman KV, Wu W, Giannini C, Krauss J, Buckner JC, et al. Phase II evaluation of gefitinib in patients with newly diagnosed grade 4 astrocytoma: Mayo/North Central Cancer Treatment Group Study N0074. Int J Radiat Oncol Biol Phys. 2011;80:347–53.PubMed

27.

Raizer JJ, Abrey LE, Lassman AB, Chang SM, Lamborn KR, Kuhn JG, et al. A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy. J Neuro-Oncol. 2009;12:95–103.

28.

Yung WA, Vredenburgh JJ, Cloughesy TF, Nghiemphu P, Klencke B, Gilbert MR, et al. Safety and efficacy of erlotinib in first-relapse glioblastoma: a phase II open-label study. J Neuro-Oncol. 2010;12:1061–70.

29.

Franceschi E, Cavallo G, Lonardi S, Magrini E, Tosoni A, Grosso D, et al. Gefitinib in patients with progressive high-grade gliomas: a multicentre phase II study by Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO). Br J Cancer. 2007;96:1047.PubMedPubMedCentral

30.

Rich JN, Reardon DA, Peery T, Dowell JM, Quinn JA, Penne KL, et al. Phase II trial of gefitinib in recurrent glioblastoma. J Clin Oncol. 2004;22:133–42.PubMed

31.

Neyns B, Sadones J, Joosens E, Bouttens F, Verbeke L, Baurain J-F, et al. Stratified phase II trial of cetuximab in patients with recurrent high-grade glioma. Ann Oncol. 2009;20:1596–603.PubMed

32.

Leshchyns’ka I, Sytnyk V, Morrow JS, Schachner M. Neural cell adhesion molecule (NCAM) association with PKCbeta2 via betaI spectrin is implicated in NCAM-mediated neurite outgrowth. J Cell Biol. 2003;161:625–39.PubMedPubMedCentral

33.

Sytnyk V, Leshchyns’ka I, Schachner M. Neural cell adhesion molecules of the immunoglobulin superfamily regulate synapse formation, maintenance, and function. Trends Neurosci. 2017;40:295–308.PubMed

34.

Hopkins K, Chandler C, Bullimore J, Sandeman D, Coakham H, Kemshead J. A pilot study of the treatment of patients with recurrent malignant gliomas with intratumoral yttrium-90 radioimmunoconjugates. Radiother Oncol. 1995;34:121–31.PubMed

35.

Papanastassiou V, Pizer B, Coakham H, Bullimore J, Zananiri T, Kemshead J. Treatment of recurrent and cystic malignant gliomas by a single intracavity injection of 131 I monoclonal antibody: feasibility, pharmacokinetics and dosimetry. Br J Cancer. 1993;67:144.PubMedPubMedCentral

36.

Jones D, Lashford L, Dicks-Mireaux C, Kemshead J. Comparison of pharmacokinetics of radiolabeled monoclonal antibody UJ13A in patients and animal models. NCI monographs: J Natl Cancer Inst. 1987:125–30.

37.

Path F, Kemshead JT, Path F. Direct injection of 90Y MoAbs into glioma tumor resection cavities leads to limited diffusion of the radioimmunoconjugates into normal brain parenchyma: a model to estimate absorbed radiation dose. I Int J Radiat Oncol Biol Phys. 1998;40:835–44.

38.

Ullrich N, Gillespie GY, Sontheimer H. Human astrocytoma cells express a unique chloride current. Neuroreport. 1996;7:1020–4.PubMed

39.

Mamelak AN, Rosenfeld S, Bucholz R, Raubitschek A, Nabors LB, Fiveash JB, et al. Phase I single-dose study of intracavitary-administered iodine-131-TM-601 in adults with recurrent high-grade glioma. J Clin Oncol. 2006;24:3644–50.PubMed

40.

Shapiro WR, Carpenter SP, Roberts K, Shan JS. 131I-chTNT-1/B mAb: tumour necrosis therapy for malignant astrocytic glioma. Expert Opin Biol Ther. 2006;6:539–45.PubMed

41.

Shahbazian MD, Grunstein M. Functions of site-specific histone acetylation and deacetylation. Annu Rev Biochem. 2007;76:75–100.PubMed

42.

Patel SJ, Shapiro WR, Laske DW, Jensen RL, Asher AL, Wessels BW, et al. Safety and feasibility of convection-enhanced delivery of Cotara for the treatment of malignant glioma: initial experience in 51 patients. Neurosurg. 2005;56:1243–53.

43.

Maggi CA. The mammalian tachykinin receptors. General pharmacology: The vascular system. 1995;26:911–44.PubMed

44.

Kneifel S, Cordier D, Good S, Ionescu MC, Ghaffari A, Hofer S, et al. Local targeting of malignant gliomas by the diffusible peptidic vector 1, 4, 7, 10-tetraazacyclododecane-1-glutaric acid-4, 7, 10-triacetic acid-substance P. Clin Cancer Res. 2006;12:3843–50.PubMed

45.

Majkowska-Pilip A, Rius M, Bruchertseifer F, Apostolidis C, Weis M, Bonelli M, et al. In vitro evaluation of 225Ac-DOTA-substance P for targeted alpha therapy of glioblastoma multiforme. Chem Biol Drug Des. 2018;92:1344–56.PubMed

46.

Królicki L, Bruchertseifer F, Kunikowska J, Koziara H, Królicki B, Jakuciński M, et al. Safety and efficacy of targeted alpha therapy with 213 Bi-DOTA-substance P in recurrent glioblastoma. Eur J Nucl Med Mol Imaging. 2019;46:614–22.PubMed

47.

Kobayashi N, Kostka G, Garbe JH, Keene DR, Bächinger HP, Hanisch F-G, et al. A comparative analysis of the fibulin protein family biochemical characterization, binding interactions, and tissue localization. J Biol Chem. 2007;282:11805–16.PubMed

48.

Giltay R, Timpl R, Kostka G. Sequence, recombinant expression and tissue localization of two novel extracellular matrix proteins, fibulin-3 and fibulin-4. Matrix Biol. 1999;18:469–80.PubMed

49.

Hu B, Thirtamara-Rajamani KK, Sim H, Viapiano MS. Fibulin-3 is uniquely upregulated in malignant gliomas and promotes tumor cell motility and invasion. Mol Cancer Res. 2009:1541-7786. MCR-09-0207.

50.

Hu B, Nandhu MS, Sim H, Agudelo-Garcia PA, Saldivar JC, Dolan CE, et al. Fibulin-3 promotes glioma growth and resistance through a novel paracrine regulation of Notch signaling. Cancer Res 2012.

51.

Nandhu MS, Kwiatkowska A, Bhaskaran V, Hayes J, Hu B, Viapiano MS. Tumor-derived fibulin-3 activates pro-invasive NF-κB signaling in glioblastoma cells and their microenvironment. Oncogene. 2017;36:4875.PubMedPubMedCentral

52.

Hiddingh L, Tannous BA, Teng J, Tops B, Jeuken J, Hulleman E, et al. EFEMP1 induces γ-secretase/Notch-mediated temozolomide resistance in glioblastoma. Oncotarget. 2014;5:363.PubMed

53.

Nandhu MS, Hu B, Cole SE, Erdreich-Epstein A, Rodriguez-Gil DJ, Viapiano MS. Novel paracrine modulation of Notch-DLL4 signaling by fibulin-3 promotes angiogenesis in high-grade gliomas. Cancer Res. 2014:canres. 0685.2014.

54.

Nandhu MS, Behera P, Bhaskaran V, Longo SL, Barrera-Arenas LM, Sengupta S, et al. Development of a function-blocking antibody against fibulin-3 as a targeted reagent for glioblastoma. Clin Cancer Res. 2018;24:821–33.PubMed

55.

Longo SL, Behera P, Viapiano MS, Nandhu MS. Inhibition of fibulin-3 reverses macrophage polarization in glioblastoma and increases anti-tumor inflammatory responses. AACR; 2018.

56.

Emrich JG, Brady LW, Quang TS, Class R, Miyamoto C, Black P, et al. Radioiodinated (I-125) monoclonal antibody 425 in the treatment of high grade glioma patients: ten-year synopsis of a novel treatment. Am J Clin Oncol. 2002;25:541–6.PubMed

57.

Zalutsky MR, Moseley RP, Coakham HB, Coleman RE, Bigner DD. Pharmacokinetics and tumor localization of 131I-labeled anti-tenascin monoclonal antibody 81C6 in patients with gliomas and other intracranial malignancies. Cancer Res. 1989;49:2807–13.PubMed

58.

Vogelbaum MA, Aghi MK. Convection-enhanced delivery for the treatment of glioblastoma. J Neuro-Oncol. 2015;17:ii3–8.

59.

Hdeib A, Sloan AE. Convection-enhanced delivery of 131I-chTNT-1/B mAB for treatment of high-grade adult gliomas. Expert Opin Biol Ther. 2011;11:799–806.PubMed

60.

Gan HK, van den Bent M, Lassman AB, Reardon DA, Scott AM. Antibody–drug conjugates in glioblastoma therapy: the right drugs to the right cells. Nat Rev Clin Oncol. 2017;14:695.PubMed

61.

Gilbert MR. Antiangiogenic therapy for glioblastoma: complex biology and complicated results. J Clin Oncol. 2016;34:1567–9.PubMed

62.

Batchelor TT, Sorensen AG, di Tomaso E, Zhang W-T, Duda DG, Cohen KS, et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell. 2007;11:83–95.PubMedPubMedCentral

63.

Taal W, Oosterkamp HM, Walenkamp AM, Dubbink HJ, Beerepoot LV, Hanse MC, et al. Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial. The lancet oncol. 2014;15:943–53.PubMed

64.

Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, Abrey LE, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol. 2009;27:4733–40.PubMed

65.

Wick W, Brandes A, Gorlia T, Bendszus M, Sahm F, Taal W, et al. LB-05 phase III trial exploring the combination of bevacizumab and lomustine in patients with first recurrence of a glioblastoma: The EORTC 26101 trial. Neuro-Oncology. 2015;17:v1–v.

66.

Quang TS, Brady LW. Radioimmunotherapy as a novel treatment regimen: 125I-labeled monoclonal antibody 425 in the treatment of high-grade brain gliomas. Int J Radiat Oncol Biol Phys. 2004;58:972–5.PubMed

67.

Gan HK, Burge M, Solomon B, Holen KD, Zhang Y, Ciprotti M, et al. A Phase 1 and biodistribution study of ABT-806i, an 111indium-labeled conjugate of thetumor-specific anti-EGFR antibody ABT-806. 2013.

68.

Van den Bent M, Roberts-Rapp L, Ansell P, Kular R, Song M, Sokolova I, et al. 2903 Identifying the correct patient (pt) population for ABT-414: biomarker assays for epidermal growth factor receptor (EGFR) in pts with glioblastoma (GBM). Eur J Cancer. 2015;51:S585–S6.

69.

DiPippo VA, Olson WC, Nguyen HM, Brown LG, Vessella RL, Corey E. Efficacy studies of an antibody-drug conjugate PSMA-ADC in patient-derived prostate cancer xenografts. Prostate. 2015;75:303–13.PubMed

70.

Scott AM, Roberts-Rapp L, Gan HK, Lu X, Lassman AB, van den Bent M, et al. ATNT-02 determinants of responses and resistance to ABT-414: results of next-generation sequencing. Neuro-Oncology. 2015;17:v10.PubMedCentral

71.

Todhunter DA, Hall WA, Rustamzadeh E, Shu Y, Doumbia SO, Vallera DA. A bispecific immunotoxin (DTAT13) targeting human IL-13 receptor (IL-13R) and urokinase-type plasminogen activator receptor (uPAR) in a mouse xenograft model. Protein Eng Des Sel. 2004;17:157–64.PubMed

72.

Rustamzadeh E, Vallera DA, Todhunter DA, Low WC, Panoskaltsis-Mortari A, Hall WA. Immunotoxin pharmacokinetics: a comparison of the anti-glioblastoma bi-specific fusion protein (DTAT13) to DTAT and DTIL13. J Neuro-Oncol. 2006;77:257–66.

73.

Stish BJ, Oh S, Vallera DA. Anti-glioblastoma effect of a recombinant bispecific cytotoxin cotargeting human IL-13 and EGF receptors in a mouse xenograft model. J Neuro-Oncol. 2008;87:51–61.

74.

Higgins SC, Fillmore HL, Ashkan K, Butt AM, Pilkington GJ. Dual targeting NG2 and GD3A using Mab-Zap immunotoxin results in reduced glioma cell viability in vitro. Anticancer Res. 2015;35:77–84.PubMed

Title: Radioimmunotherapy (RIT) in Brain Tumors
Authors: Ali Gholamrezanezhad
Hossein Shooli
Narges Jokar
Reza Nemati
Majid Assadi
Publication date: 01-12-2019
Publisher: Springer Berlin Heidelberg
Keywords: Glioblastoma
Radioimmunotherapy
Glioma
Glioma
Glioblastoma
Brain Tumor
Glioblastoma
Glioma
Published in: Nuclear Medicine and Molecular Imaging / Issue 6/2019
Print ISSN: 1869-3474
Electronic ISSN: 1869-3482
DOI: https://doi.org/10.1007/s13139-019-00618-6

At a glance: The STEP trials

Springer Medicine

Radioimmunotherapy (RIT) in Brain Tumors

Abstract

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 6/2019

Reverse Warburg Effect-Related Mitochondrial Activity and 18F-FDG Uptake in Invasive Ductal Carcinoma

Comparative Analysis of Lung Perfusion Scan and SPECT/CT for the Evaluation of Functional Lung Capacity

Orbital IgG4 Disease: Imaging Findings on 68Ga-DOTANOC PET/CT

Perspectives in TSPO PET Imaging for Neurologic Diseases

Effect of ME Collimator Characteristic, Energy Window Width, and Reconstruction Algorithm Selection on Imaging Performance of Yttrium-90: Simulation Study

Intramastoid Phosphaturic Mesenchymal Tumor Causing Hypophosphatemic Osteomalacia Detected on 68Ga-DOTATATE PET/CT But Not on 99mTc-Sestamibi and 18F-FDG Scans